Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BDSX 
Biodesix Inc (BDSX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BDSX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $1.75
1 Year Target Price $1.75
| 4 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -49.94% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 65.46M USD | Price to earnings Ratio - | 1Y Target Price 1.75 |
Price to earnings Ratio - | 1Y Target Price 1.75 | ||
Volume (30-day avg) 6 | Beta 0.98 | 52 Weeks Range 0.17 - 2.00 | Updated Date 08/29/2025 |
52 Weeks Range 0.17 - 2.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.07 | Actual -0.08 |
Profitability
Profit Margin -53.66% | Operating Margin (TTM) -48.42% |
Management Effectiveness
Return on Assets (TTM) -20.81% | Return on Equity (TTM) -219.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 116870128 | Price to Sales(TTM) 0.85 |
Enterprise Value 116870128 | Price to Sales(TTM) 0.85 | ||
Enterprise Value to Revenue 1.53 | Enterprise Value to EBITDA -2.72 | Shares Outstanding 146632992 | Shares Floating 62040571 |
Shares Outstanding 146632992 | Shares Floating 62040571 | ||
Percent Insiders 52.13 | Percent Institutions 24.32 |
Upturn AI SWOT
Biodesix Inc
Company Overview
History and Background
Biodesix, Inc. was founded in 2005 and is a molecular diagnostics company that develops and commercializes tests for lung disease. It went public in 2020.
Core Business Areas
- Lung Diagnostic Tests: Develops and commercializes blood-based diagnostic tests for lung cancer and other lung diseases. Focuses on improving patient outcomes through earlier and more accurate diagnoses.
Leadership and Structure
The leadership team includes Scott Hutton (CEO) and other executives. The company has a standard corporate structure with departments for R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Nodify Lung Nodule Risk Assessment: A blood-based test that helps physicians assess the risk of malignancy in lung nodules. Market share data is not publicly available for this specific test. Competitors include Veracyte and other molecular diagnostics companies in the lung cancer space.
- LungStrat Dx EGFR Mutation Test: Identifies EGFR mutations in lung cancer patients. Market share data is not publicly available for this specific test. Competitors include Roche, Thermo Fisher Scientific, and other companies offering EGFR testing solutions.
Market Dynamics
Industry Overview
The molecular diagnostics market is growing due to the increasing prevalence of diseases like cancer and the demand for personalized medicine.
Positioning
Biodesix aims to be a leader in lung cancer diagnostics by providing innovative blood-based tests that improve patient care.
Total Addressable Market (TAM)
The total addressable market for lung cancer diagnostics is estimated to be in the billions of dollars. Biodesix is positioned to capture a share of this market with its portfolio of tests.
Upturn SWOT Analysis
Strengths
- Proprietary diagnostic technologies
- Focus on lung diseases
- Established commercial infrastructure
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on reimbursement for test adoption
- Relatively small market capitalization
Opportunities
- Expanding the test menu to cover other lung diseases
- Strategic partnerships with pharmaceutical companies
- Increasing awareness of the benefits of blood-based diagnostics
Threats
- Competition from larger diagnostic companies
- Changes in reimbursement policies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- Veracyte (VCYT)
- Exact Sciences (EXAS)
- Guardant Health (GH)
Competitive Landscape
Biodesix is a smaller player compared to competitors like Veracyte and Exact Sciences. Its competitive advantage lies in its focus on lung diseases and its proprietary diagnostic technologies. However, it faces challenges related to limited financial resources and reimbursement.
Growth Trajectory and Initiatives
Historical Growth: Biodesix's historical growth has been driven by the adoption of its lung diagnostic tests.
Future Projections: Future growth is expected to be driven by expanding the test menu, strategic partnerships, and increasing market penetration.
Recent Initiatives: Recent initiatives include expanding the commercial team, investing in R&D, and pursuing strategic partnerships.
Summary
Biodesix is a molecular diagnostics company focused on lung diseases. It has proprietary technologies and a growing portfolio of tests. However, it faces competition from larger companies and challenges related to reimbursement and financial resources. Strategic partnerships and test menu expansion are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Financial data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biodesix Inc
Exchange NASDAQ | Headquaters Louisville, CO, United States | ||
IPO Launch date 2020-10-28 | President, CEO & Director Mr. Scott Hutton | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 273 | Website https://www.biodesix.com |
Full time employees 273 | Website https://www.biodesix.com | ||
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.